140 related articles for article (PubMed ID: 32030447)
21. Immunosuppressive therapy for elderly-acquired pure red cell aplasia: cyclosporine A may be more effective.
Liu X; Lu X; Chen L; Yang Y; Wu X; Lu R; Wang S; Zhang J; Hong M; Zhu Y; He G; Li J
Ann Hematol; 2020 Mar; 99(3):443-449. PubMed ID: 31970447
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporin A for the treatment of pure red cell aplasia associated with myelodysplasia.
Grigg AP; O'Flaherty E
Leuk Lymphoma; 2001; 42(6):1339-42. PubMed ID: 11911417
[TBL] [Abstract][Full Text] [Related]
24. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
[TBL] [Abstract][Full Text] [Related]
25. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit?
Tanna S; Ustun C
Int J Hematol; 2009 Dec; 90(5):597-600. PubMed ID: 19760482
[TBL] [Abstract][Full Text] [Related]
27. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
28. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
Peddi VR; Jensik S; Pescovitz M; Pirsch J; Adler SH; Thistlethwaite JR; Vincenti F; Cohen DJ
Clin Transplant; 2005 Feb; 19(1):130-6. PubMed ID: 15659146
[TBL] [Abstract][Full Text] [Related]
29. Case report: Dynamic antibody monitoring in a case of anti-recombinant human erythropoietin-mediated pure red cell aplasia with prolonged course after kidney transplantation.
Chen XM; Li H; Wu Y; Wang LL; Bai YJ; Shi YY
Front Immunol; 2022; 13():1049444. PubMed ID: 36524109
[TBL] [Abstract][Full Text] [Related]
30. Acquired pure red cell aplasia: updated review of treatment.
Sawada K; Fujishima N; Hirokawa M
Br J Haematol; 2008 Aug; 142(4):505-14. PubMed ID: 18510682
[TBL] [Abstract][Full Text] [Related]
31. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
32. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.
Groth CG; Bäckman L; Morales JM; Calne R; Kreis H; Lang P; Touraine JL; Claesson K; Campistol JM; Durand D; Wramner L; Brattström C; Charpentier B
Transplantation; 1999 Apr; 67(7):1036-42. PubMed ID: 10221490
[TBL] [Abstract][Full Text] [Related]
33. Acquired pure red cell aplasia in Japan.
Mamiya S; Itoh T; Miura AB
Eur J Haematol; 1997 Oct; 59(4):199-205. PubMed ID: 9338617
[TBL] [Abstract][Full Text] [Related]
34. A case report of a patient who has pure red cell aplasia and rheumatoid arthritis.
Ustün C; Karavelioğlu D; Ilhan O; Aydintuğ O; Beksaç M
Int J Hematol; 1997 Dec; 66(4):505-12. PubMed ID: 9479876
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia.
Chikkappa G; Pasquale D; Zarrabi MH; Weiler RJ; Divakara M; Tsan MF
Am J Hematol; 1992 Sep; 41(1):5-12. PubMed ID: 1503099
[TBL] [Abstract][Full Text] [Related]
36. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
Zhu L; Ding T; Wang XX; Lin ZB; Chen G
Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
[TBL] [Abstract][Full Text] [Related]
37. Pure red cell aplasia associated to clonal CD8+ T-cell large granular lymphocytosis: dependence on cyclosporin A therapy.
Coutinho J; Lima M; dos Anjos Teixeira M; Cabeda JM; Leite F; Justiça B
Acta Haematol; 1998; 100(4):207-10. PubMed ID: 9973645
[TBL] [Abstract][Full Text] [Related]
38. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
[TBL] [Abstract][Full Text] [Related]
39. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
[TBL] [Abstract][Full Text] [Related]
40. [Acquired pure red cell aplasia in a patient with B cell chronic lymphocytic leukemia after fludarabine therapy].
Tsuji T; Hirano T; Yamasaki H; Tuda H
Rinsho Ketsueki; 2015 Jun; 56(6):705-10. PubMed ID: 26256883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
